Innovating Works

Oblita

Desconocido
TT4CL: Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutane... OBLITA THERAPEUTICS participó en un H2020: H2020-SC1-BHC-2018-2020 Cutaneous leishmaniasis (CL) is a poverty related, neglected tropical disease, which is without an effective and cheap systemic treatment. T...
2019-04-30 - 2024-07-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.